박지영 (서울대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회1,893

서울대학교 의과대학

CV File

Trends Pharmacol. Sci., Available online 9 December 2021 | https://doi.org/10.1016/j.tips.2021.11.013 [Spotlight]Will ETA-antibody arouse new interest in cancer therapeutics?

Ji-Young Park¹, Chang-Han Lee^1,2,3,4,5,*

¹Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
²Department of Pharmacology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
³BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
⁴SNU Dementia Research Center, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
⁵Wide River Institute of Immunology, Seoul National University, Hongcheon 25159, Republic of Korea

^*Correspondence

Abstract

Although endothelin receptor type A (ETA) is emerging as a novel anticancer target, previously only small molecule drugs have been available as ETA antagonists. Ju and colleagues have successfully developed a functional anti-ETA antibody for colorectal cancer.

Keywords : GPCR, ETA antagonist, therapeutic antibody, cancer stem cell

논문정보